CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Garo Armen

Chairman & Chief Executive Officer (also interim CFO/Principal Financial Officer as of early 2026), Agenus Inc.

Search every verified Garo Armen interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Garo Armen, chairman and chief executive officer of Agenus, discussed the company's progress in advancing its investigational combination therapy botensilimab plus balstilimab (BOT+BAL) during a September 2026 stakeholder webcast. He highlighted preparations for the global Phase 3 ROBBIN study in high-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer and noted continued physician interest in access pathways for the treatment. Armen also described the clinical rationale for using the combination in the neoadjuvant setting, stating that "the best time to prime is when there's a tumor present" and that the therapy works more efficiently before surgery than after. Armen also addressed the company's access programs, including one approved in France, noting that while the number of treated patients has not been disclosed, Agenus has reported quarterly reimbursement revenue from the French government. He expressed confidence in the team's ability to achieve the company's near-term targets, saying they are focused on delivering results "over the next months, not next year or two."

Recent appearances

  • Agenus Stakeholder Webcast | September 2026

    September 11, 2026 · 📺 Agenus Bio

    Agenus’ September 2026 Stakeholder Webcast provides an update on the company’s progress advancing botensilimab plus balstilimab (BOT+BAL), including preparations for the global Phase 3 ROBBIN study in high-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer. The webcast features: • Garo Armen, PhD, Chairman and Chief Executive Officer • Steven O’Day, MD, Chief Medical Officer • Robin Taylor, PhD, Chief Commercial Officer • Benjamin Schlechter, MD, senior physician at Dana-Farber Cancer Institute • Stefanie Perna-Nacar, Chief Communications Officer Topics include: • Operati…

    Watch on YouTube ↗

  • Agenus Conference Call on Financing and ROBBIN Trial Strategy | July 13, 2026

    July 16, 2026 · 📺 i101

    Agenus Conference Call on Financing and ROBBIN Trial Strategy | July 13, 2026. Twitter - https://x.com/i101yt If you find our work ...

    Watch on YouTube ↗

  • Episode 16 | Global Health Dialogues with Princess Dina and Dr Garo Armen

    May 11, 2026 · 📺 Global Health Dialogues with Princess Dina

    In this episode, Princess Dina sits down with Dr. Garo Armen, Chairman and CEO of Agenus, to explore the promise and limits of ...

    Watch on YouTube ↗

  • EPISODE 3: Garo Armen, CEO of Agenus and chairman of the Children of Armenia Fund

    March 11, 2026 · 📺 Jim Moran College of Entrepreneurship

    Welcome to the Bridging Minds FSU x ASUE Podcast Series on Armenian Entrepreneurship, where we spotlight innovation, resilience, and entrepreneurship across borders. Hosted by Madison Miller, Research Assistant at Florida State University’s Jim Moran College of Entrepreneurship, this episode features Garo Armen, the CEO of Agenus and chairman of the Children of Armenia Fund. Together, we explore his entrepreneurial journey, the challenges he’s overcome, and the meaningful impact he’s creating through innovation and purpose. This podcast series was funded by the grant SAM10024CA0023-M001 “Pro…

    Watch on YouTube ↗

  • Agenus Webcast January 2026 | Access to Acceleration: BOT+BAL Global Momentum Entering 2026

    January 29, 2026 · 📺 Agenus Bio

    In this recorded Agenus stakeholder webcast, Garo Armen is joined by leading oncology experts to discuss expanding patient access to next-generation immunotherapy and Agenus’ momentum entering 2026. Highlights include a clinical discussion with Robin Jones (Royal Marsden Hospital) on sarcoma and immunotherapy, the expansion of France’s reimbursed AAC early-access pathway to sarcoma and ovarian cancer, and an update on Agenus’ strategic collaboration with Zydus Lifesciences, strengthening U.S.-based biologics manufacturing. The webcast also covers growing global physician demand, real-world ev…

    Watch on YouTube ↗

  • Agenus December 2025 Stakeholder Engagement Webcast

    December 04, 2025 · 📺 Agenus Bio

    Join us for Agenus’ End-of-Year 2025 Webcast featuring leading GI oncologists and a powerful caregiver-physician story that brings the BOT/BAL journey to life. Hear how immunotherapy expectations in MSS colorectal cancer are shifting, get an inside look at the global Phase 3 BATTMAN trial, and learn how innovative approaches may change the path forward for patients. Featuring: • Dr. Christopher Lieu — evolving role of IO in CRC • Dr. Jonathan Loree — Phase 3 global trial momentum • Dr. Benny Johnson — a personal early-onset CRC journey and clinical-trial decision-making Moderated by Garo Arm…

    Watch on YouTube ↗

  • Global Momentum: BOT/BAL Across Borders | Agenus Stakeholder Briefing – October 2025

    October 22, 2025 · 📺 Agenus Bio

    This October 2025 Stakeholder Briefing features new data from ESMO 2025 and international access milestones advancing Agenus' immunotherapy combination, botensilimab (BOT) and balstilimab (BAL) for patients with hard-to-treat cancers. Featured Speakers: • Dr. Michael Gordon, Chief Medical Officer, HonorHealth Research Institute – reviews updated Phase 1b pan-tumor data presented at ESMO 2025, spanning more than 400 patients with refractory solid tumors. • Professor Alexander Eggermont, global immuno-oncology expert and former Director General of Gustave Roussy Cancer Center (France) – discuss…

    Watch on YouTube ↗

  • Armenia’s Future: From Biotech Breakthroughs to Fintech Revolutions

    October 16, 2025 · 📺 DigiTec

    Dr. Garo Armen is a renowned Armenian-American scientist, entrepreneur, and philanthropist. As Chairman and CEO of Agenus Inc., which he co-founded in 1994, he has become one of the leading figures in the global biotechnology sector. Beyond his corporate leadership, Dr. Armen is best known for founding the Children of Armenia Fund (COAF) — a transformative initiative that has invested over $100 million to revitalize rural communities across Armenia. A recipient of the Ellis Island Medal of Honor, the Sabin Humanitarian Award, and the Prime Minister’s Medal of Honor of Armenia, Dr. Armen embodi…

    Watch on YouTube ↗

  • ATOM Dialogues: Dr. Garo Armen and Nouneh Sarkissian

    September 29, 2025 · 📺 ATOM

    ATOM (Advanced Tomorrow) Dialogues Dr. Garo Armen and Nouneh Sarkissian www.advancedtomorrow.com.

    Watch on YouTube ↗

  • Dr. Garo H. Armen | 04-27-25

    May 31, 2025 · 📺 Red Apple Podcast Network

    Roger talks with Dr. Garo H. Armen on if Big Pharma and some professionals in the medical industry are suppressing research and findings on a potential cure for cancer, natural remedies, and more. Learn more about your ad choices. Visit megaphone.fm/adchoices (https://megaphone.fm/adchoices)

    Watch on YouTube ↗

  • Garo Armen | Agenus | Biotech Advancing Cancer Treatment

    May 03, 2025 · 📺 Hyeland Project

    Garo Armen is the Chairman and CEO of Agenus, a pioneering biotech company advancing cancer treatment. He is founder of the Children of Armenia Fund (COAF), an organization dedicated to revitalizing rural Armenia by building modern schools, healthcare facilities, and community programs, significantly enhancing the quality of life and opportunities for local children and families. Armenian American Forum 2025 https://tennessee.hyelandproject.com/...

    Watch on YouTube ↗

  • Celebrating Innovation: Dr. Garo Armen Receives WITSA Eminent Person Award!

    November 04, 2024 · 📺 Children of Armenia Fund

    Join us as Dr. Garo Armen, Founder of COAF and Founding Director of Agenus Inc., shares insights at a recent press conference ...

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →